| Partnerships | Amount | Deal | Date |
| Gilead and Nurix | $15 mil upfront | Collaboration Extension | April 2024 |
| Novartis and Arvinas | $150 mil upfront | ARV-766 development | April 2024 |
| VantAI and BMS | $674 mil upfront | Collaboration, molecular glues | Feb 2024 |
| VantAI and BluePrint | | Collaboration, TPD | Feb 2022 |
| Sanofi and Kymera | $150 mil upfront | Collaboration, TPD, immunology and oncology | Jul 2020 |
| Cullgen and Astellas | $35 mil upfront | Collaboration, protein degraders | Jun 2023 |
| Orionis and Novartis | | Collaboration, molecular glue degraders, Allo-Glue | Mar 2020 |
| Orionis and Genentech | $47 mil upfront | Collaboration, molecular glue degraders, Allo-Glue | Sept 2023 |
| MonteRosa and Roche | $50 mil upfront | Collaboration, molecular glue degraders, Queens platform | Oct 2023 |
| Kymera and Neosphere | | Collaboration, molecular glue degraders, Proteomics | May 2024 |
| C4 and Merck | $10 mil upfront | Collaboration, license, degrader-antibody conjugate (DAC) | Dec 2023 |
| Seagen and Nurix | $60 mil upfront | Collaboration, degrader-antibody conjugate (DAC) | Sept 2023 |
| Merck and Proxygen | | Collaboration, molecular glue degraders | April 2023 |
| C4 and Biogen | $415 mil upfront | Collaboration, Neuroscience, TPD | Jan 2019 |
| Neomorph and NovoNordisk | | Collaboration, license, glue degraders, cardiovascular and rare diseases | Feb 2024 |
